Meeting
2022 ASCO Annual Meeting
Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).
Authors
Xiuning Le
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Xiuning Le , Luis Paz-Ares , Jan Van Meerbeeck , Santiago Viteri Ramirez , Carlos Cabrera Galvez , David Vicente Baz , Young-Chul Kim , Jin-Hyoung Kang , Christopher Stroh , Dilafruz Juraeva , Rolf Bruns , Gordon Otto , Andreas Johne , Paul K. Paik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02864992
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9121)
DOI
10.1200/JCO.2022.40.16_suppl.9121
Abstract #
9121
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
First Author: Xiuning Le
Poster
2023 ASCO Annual Meeting
Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.
First Author: Daniel Shao-Weng Tan
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee
Poster
2023 ASCO Annual Meeting
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
First Author: Christian Diego Rolfo